BiotechTube
CRISPR QC

CRISPR QC

Cambridge, United States· Est.
crisprqc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

CRISPR QC is a private, early-stage company founded in 2016 and based in Cambridge, USA, operating at the intersection of CRISPR tools and diagnostics. The company has developed the CRISPR Analytics Platform™, a first-of-its-kind service that uses a proprietary graphene-based biosensor (CRISPR-Chip™) to provide real-time, quantitative data on the biochemical efficiency of CRISPR-Cas components. This platform is positioned as a critical quality control and optimization tool for researchers and developers, helping to identify inefficiencies early, reduce costly trial-and-error, and accelerate timelines from discovery to commercialization.

CRISPRDiagnostics

Technology Platform

CRISPR Analytics Platform™ featuring the CRISPR-Chip™, a graphene-based biosensor for real-time, label-free, quantitative measurement of CRISPR-Cas biochemical kinetics (RNP formation, DNA binding, cleavage activity).

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The massive and growing global CRISPR R&D market creates a direct need for tools to de-risk and accelerate workflows.
Long-term opportunity exists in expanding from research services into quality control for clinical manufacturing of CRISPR-based therapies.
The platform's modularity allows for expansion into analyzing novel CRISPR systems like base and prime editors.

Risk Factors

Risk of slow adoption as researchers may be reluctant to change established workflows.
Potential for competition from large life science tool companies or new entrants.
The company's growth is tied to the broader CRISPR market's expansion and could be affected by technological shifts in the field.

Competitive Landscape

CRISPR QC appears to be a first-mover with a specialized, hardware-based platform for real-time CRISPR kinetics. Potential competitors include providers of indirect, endpoint assay kits (e.g., gel electrophoresis, NGS-based cleavage assays) and companies developing alternative biophysical characterization tools. Large life science tools corporations could enter the space, posing a significant competitive threat.

More companies in CRISPR / Gene Editing →More companies in United States →